RESULTS: PD patients showed instable gait with insufficient range of motion during usual walking. Active taVNS improved gait characteristics including step length, stride velocity, stride length, and step length variability compared with sham taVNS after completion of the 7-day therapy. No difference was found in the Unified Parkinson's Disease Rating Scale III, Timed Up and Go, Tinetti Balance, and Gait scores. Moreover, PD patients had higher relative change of oxyhemoglobin in the left dorsolateral prefrontal cortex, pre-motor area, supplementary motor area, primary motor cortex, and primary somatosensory cortex than HCs group during usual walking. Hemodynamic responses in the left primary somatosensory cortex were significantly decreased after taVNS therapy.
CONCLUSION: taVNS can relieve gait impairments and remodel sensorimotor integration in PD patients. 1
RESULTS: The left taVNS induced a reduction of the total β power in the contralateral (ie, right) subthalamic nucleus and an improvement of TUG time, speed, and variability. The taVNS-induced β reduction correlated with the improvement of gait speed. No major clinical changes were observed at UPDRS.
CONCLUSIONS: taVNS is a promising strategy for the management of PD gait, deserving prospective trials of chronic neuromodulation. 2
1. Zhang H, Cao XY, Wang LN, et al. Transcutaneous auricular vagus nerve stimulation improves gait and cortical activity in Parkinson’s disease: A pilot randomized study. CNS Neurosci Ther. Published online June 13, 2023. doi:10.1111/cns.14309
2. Marano M, Anzini G, Musumeci G, et al. Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson’s Disease. Mov Disord Off J Mov Disord Soc. 2022;37(10):2163-2164. doi:10.1002/mds.29166